最严重肝硬化患者的肝移植:慢加急性肝衰竭3级的多中心研究
该多中心回顾性研究纳入73例在三个肝ICU接受肝移植的ACLF-3级肝硬化患者,并与未移植的多器官功能障碍患者及较低ACLF级别移植患者匹配比较。ACLF-3级移植患者1年生存率83.9%,高于未移植对照的7.9%(p<0.0001),与无ACLF、ACLF-1、ACLF-2级移植患者无差异,但并发症发生率更高、住院时间更长。
要点
- ACLF-3级肝硬化患者肝移植后1年生存率83.9%,显著高于未移植对照的7.9%。
- ACLF-3级移植患者1年生存率与无ACLF(90%)、ACLF-1(82.3%)、ACLF-2(86.2%)移植患者无差异。
- ACLF-3级移植患者并发症发生率100%,高于无ACLF(51.2%)、ACLF-1(76.5%)、ACLF-2(74.3%)患者。
核心结论
- 肝移植强烈影响ACLF-3级肝硬化患者的生存,其1年生存率与较低ACLF级别移植患者相似。
- 由于「移植窗口」较短,需要快速决策,ACLF-3级患者应迅速转诊至专门的肝ICU。
研究设计与样本
- 多中心回顾性研究,纳入三个肝ICU中所有接受肝移植的ACLF-3级患者。
- 每例ACLF-3级移植患者与未移植的ICU多器官功能障碍患者或接受移植的较低ACLF级别(无ACLF、ACLF-1、ACLF-2)对照患者匹配。
- 共纳入73例患者。
主要发现
- ACLF-3级移植患者经稳定病情管理后接受移植,入院至移植中位时间为9天,平均器官衰竭数从4.03降至3.67(p=0.009)。
- ACLF-3级移植患者1年生存率83.9%,高于未移植对照的7.9%(p<0.0001)。
- ACLF-3级移植患者1年生存率与无ACLF(90%)、ACLF-1(82.3%)、ACLF-2(86.2%)移植患者无差异。
- ACLF-3级移植患者并发症发生率100%,分别高于无ACLF(51.2%)、ACLF-1(76.5%)、ACLF-2(74.3%)移植患者,且住院时间更长。
临床怎么用
- 作者认为ACLF-3级肝硬化患者应迅速转诊至专门的肝ICU,并快速做出移植决策以避免高死亡风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Liver transplantation (LT) for the most severely ill patients with cirrhosis, with multiple organ dysfunction (accurately assessed by the acute-on-chronic liver failure [ACLF] classification) remains controversial. We aimed to report the results of LT in patients with ACLF grade 3 and to compare these patients to non-transplanted patients with cirrhosis and multiple organ dysfunction as well as to patients transplanted with lower ACLF grade. METHODS: All patients with ACLF-3 transplanted in three liver intensive care units (ICUs) were retrospectively included. Each patient with ACLF-3 was matched to a) non-transplanted patients hospitalized in the ICU with multiple organ dysfunction, or b) control patients transplanted with each of the lower ACLF grades (three groups). RESULTS: Seventy-three patients were included. These severely ill patients were transplanted following management to stabilize their condition with a median of nine days after admission (progression of mean organ failure from 4.03 to 3.67, p=0.009). One-year survival of transplanted patients with ACLF-3 was higher than that of non-transplanted controls: 83.9 vs. 7.9%, p<0.0001. This high survival rate was not different from that of matched control patients with no ACLF (90%), ACLF-1 (82.3%) or ACLF-2 (86.2%). However, a higher rate of complications was observed (100 vs. 51.2 vs. 76.5 vs. 74.3%, respectively), with a longer hospital stay. The notion of a "transplantation window" is discussed. CONCLUSIONS: LT strongly influences the survival of patients with cirrhosis and ACLF-3 with a 1-year survival similar to that of patients with a lower grade of ACLF. A rapid decision-making process is needed because of the short "transplantation window" suggesting that patients with ACLF-3 should be rapidly referred to a specific liver ICU. Lay summary: Liver transplantation improves survival of patients with very severe cirrhosis. These patients must be carefully monitored and managed in a specialized unit. The decision to transplant a patient must be quick to avoid a high risk of mortality.
引用
- Artru F, Louvet A, Ruiz I, et al. Liver transplantation in the most severely ill cirrhotic patients: A multicenter study in acute-on-chronic liver failure grade 3. J Hepatol. 2017. PMID: 28645736. doi:10.1016/j.jhep.2017.06.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。